Capricor Therapeutics (CAPR) Retained Earnings (2010 - 2026)
Capricor Therapeutics (CAPR) recorded quarterly Retained Earnings of -$253727.0 in Q1 2026, up 99.92% quarter-over-quarter from -$304.9 million in Q4 2025, and up 99.89% on a YoY basis from -$126935.3 in Q1 2025.
Capricor Therapeutics (CAPR) Retained Earnings (2010 - 2026) Analysis & Trends
Capricor Therapeutics' Retained Earnings history runs 17 years deep, the most recent figure standing at -$253727.0 for Q1 2026.
- In Q1 2026, Retained Earnings rose 99.89% year-over-year to -$253727.0; the TTM figure through Mar 2026 stood at -$253727.0 (up 99.89% YoY), while the FY2025 annual figure was -$304.9 million, down 29787.62% from the prior year.
- Retained Earnings was -$253727.0 for Q1 2026 at Capricor Therapeutics, up from -$304.9 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $1.0 million in Q4 2024 to a low of -$304.9 million in Q4 2025.
- Historically, Retained Earnings has averaged -$104.2 million across 5 years, with a median of -$115.9 million in 2022.
- The sharpest annual moves came in 2024 and 2025: Retained Earnings surged 335.5% in 2024, then plunged 161468.37% in 2025.
- A 5-year view of Retained Earnings shows it stood at $105244.0 in 2022, then jumped by 124.06% to $235813.0 in 2023, then surged by 335.5% to $1.0 million in 2024, then plunged by 29787.62% to -$304.9 million in 2025, then soared by 99.92% to -$253727.0 in 2026.
- The last three Retained Earnings figures came in at -$253727.0 (Q1 2026), -$304.9 million (Q4 2025), and -$274.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -279.00 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | 130.89 Mn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -838.07 Mn |
| 10 | Capricor Therapeutics | 1.53 Bn | 1.26 Bn | - | -253,727.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -253,727.00 |
| Dec 31, 2025 | -304.88 Mn |
| Sep 30, 2025 | -274.70 Mn |
| Jun 30, 2025 | -250.10 Mn |
| Mar 31, 2025 | -224.23 Mn |
| Dec 31, 2024 | 1.03 Mn |
| Sep 30, 2024 | -192.70 Mn |
| Jun 30, 2024 | 154,987.00 |
| Mar 31, 2024 | 307,701.00 |
| Dec 31, 2023 | 235,813.00 |
| Sep 30, 2023 | -158.61 Mn |
| Jun 30, 2023 | 179,693.00 |
| Mar 31, 2023 | 94,986.00 |
| Dec 31, 2022 | 105,244.00 |
| Sep 30, 2022 | -129.36 Mn |
| Jun 30, 2022 | -122.99 Mn |
| Mar 31, 2022 | -115.88 Mn |
| Dec 31, 2021 | -108.06 Mn |
| Sep 30, 2021 | -101.87 Mn |
| Jun 30, 2021 | -97.94 Mn |